Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 272 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MRA Clear all
Not listed Phase 2 Interventional

Comparison of Redo PVI With vs. Without Renal Denervation for Recurrent AF After Initial PVI

NCT01959997
View directory record Official record
Conditions
Atrial Fibrillation, Arterial Hypertension
Interventions
Redo PVI, PVI + RDN
Procedure
Lead sponsor
Meshalkin Research Institute of Pathology of Circulation
Network
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Oct 25, 2026, 1:09 AM EDT
Recruiting Phase 1 Interventional

Tocilizumab-aazg for Hemorrhage: Reduction of Ischemic Vascular Events

NCT06863480
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia
Interventions
tocilizumab-aazg (TYENNE)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 25, 2026, 1:09 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

NCT05207670
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
39
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 25, 2026, 1:09 AM EDT
Not yet recruiting Not applicable Interventional

Effectiveness of Artificial-Intelligence (AI) Bolus Priming Added to an Existing Fully Automated Control Algorithm (AIDANET)

NCT07517770
View directory record Official record
Conditions
Type 1 Diabetes Mellitis
Interventions
Hybrid Closed Loop (HCL) x 2 weeks, AIDANET x 2 weeks, AIDANET AI x 4 weeks
Device
Lead sponsor
Sue Brown
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Results available

A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors

NCT01331837
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Etanercept, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
3,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
143
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 25, 2026, 1:09 AM EDT
Not yet recruiting No phase listed Observational

Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis

NCT06016517
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Etanercept, Adalimumab, Upadacitinib, Tocilizumab
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis

NCT01007435
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo to tocilizumab, Methotrexate, Placebo to methotrexate
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
61
States / cities
Anniston, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 2Phase 3 Interventional

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

NCT04349410
View directory record Official record
Conditions
CoVid 19 Positive
Interventions
Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin, Hydroxychloroquine, Clindamycin, Primaquine - low dose., Hydroxychloroquine, Clindamycin, Primaquine - high dose., Remdesivir, Tocilizumab, Methylprednisolone, Interferon-Alpha2B, Losartan, Convalescent Serum
Drug
Lead sponsor
The Camelot Foundation
Other
Eligibility
Not listed
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

NCT02385110
View directory record Official record
Conditions
Leukemia
Interventions
Alemtuzumab, Etoposide, Dexamethasone, Methotrexate, Phone Call, Tocilizumab
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 25, 2026, 1:09 AM EDT
Completed No phase listed Observational Results available

A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis

NCT06418529
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
21,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 25, 2026, 1:09 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)

NCT02997956
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Tocilizumab, Transcatheter Arterial Chemoembolization
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 25, 2026, 1:09 AM EDT
Terminated Phase 1 Interventional

Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant

NCT03588936
View directory record Official record
Conditions
Acute Leukemia, Chronic Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
Nivolumab (.25 mg/kg), Tocilizumab, Nivolumab (.5 mg/kg)
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Short-Term Application of Tocilizumab Following Myocardial Infarction

NCT02419937
View directory record Official record
Conditions
Myocardial Infarction
Interventions
Tocilizumab, Placebo
Drug
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years to 89 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Results available

Tocilizumab Real-Life Human Factors (RLHFs) Validation Study

NCT02682823
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AI-1000 G2, Tocilizumab
Device · Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
8
States / cities
Mesa, Arizona • Los Alamitos, California • Santa Maria, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Oct 25, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Neutralizing Interleukin (IL)-6

NCT07493317
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Tocilizumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

NCT03434730
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorder, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Leukemia
Interventions
Total Body Irradiation, Cyclosporine, Mycophenolate Mofetil, Tocilizumab, Filgrastim
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 1:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Efficacy of Gadoterate Meglumine in Diagnosis of Vascular Diseases Using MRA MRA

NCT05199792
View directory record Official record
Conditions
Vascular Diseases
Interventions
Dotarem
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 25, 2026, 1:09 AM EDT
Not yet recruiting Phase 3 Interventional

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

NCT07335562
View directory record Official record
Conditions
Systemic Sclerosis
Interventions
BMS-986353, Fludarabine, Cyclophosphamide, Tocilizumab, Rituximab, Nintedanib
Drug
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Industry
Eligibility
16 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
17
States / cities
Scottsdale, Arizona • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 4 Interventional Results available

A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)

NCT01734382
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant

NCT03699631
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Tacrolimus, Methotrexate, Tocilizumab
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 25, 2026, 1:09 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus

NCT05155345
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Mosunetuzumab, Tocilizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 25, 2026, 1:09 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

NCT03999749
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Nivolumab, Tocilizumab
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 25, 2026, 1:09 AM EDT
Terminated Phase 1 Interventional

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

NCT04070781
View directory record Official record
Conditions
Steroid Refractory GVHD, Graft Vs Host Disease
Interventions
Itacitinib, Tocilizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Oct 25, 2026, 1:09 AM EDT
Recruiting Phase 2 Interventional

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

NCT07108387
View directory record Official record
Conditions
Giant Cell Arteritis (GCA)
Interventions
Tocilizumab, Discontinue Tocilizumab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
50 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 25, 2026, 1:09 AM EDT